Merck shares dip as 2026 outlook misses Wall Street expectations

Merck guided 2026 revenue of $65.5–$67.0 billion and adjusted EPS of $5.00–$5.15, below Street estimates of $67.6 billion and $5.36, respectively, and included a roughly $9 billion one‑time charge tied to the Cidara acquisition. Q4 adjusted EPS beat at $2.04 (vs. $2.01 est.) and revenue rose 5% to $16.4 billion (vs. $16.19B est.), with Keytruda driving full‑year sales of $31.7 billion; management flagged upcoming patent expirations (Januvia, Janumet, Bridion and Keytruda in 2028), plans $3 billion of cost cuts by 2027, and continued investment in new launches such as WINREVAIR and CAPVAXIVE. The below‑consensus outlook and patent headwinds pressured the stock (down ~2% at the open).

Analysis

Contrarian angles: The market may over-penalize Merck for one-time charges—if management executes $3bn cost cuts and pipeline M&A fills ~60–80% of lost sales, upside re-rate is plausible post-2026; short-term fear could create a buying window. Historical parallels: large pharmas (e.g., PFE, NVS) experienced 12–24 month troughs post-guidance misses followed by multi-year recovery when new launches offset LOE—look for similar cadence here. Unintended consequence: aggressive shorting of MRK could overshoot credit markets, creating arbitrage for investors to buy bonds and hedge equity, compressing spreads and limiting equity downside.

Key Decisions for Investors

• Establish a tactical hedge: buy a 6‑month MRK put spread 10–12% OTM with a 10% width sized to 0.5–1% of portfolio to protect against further guidance downgrades over the next 3–6 months.
• If MRK equity drops another 5–10% or forward P/E < 12x (implied by adjusted EPS ~ $5.00), build a core long position equal to 2–3% of portfolio with a 12–36 month horizon to capture pipeline and cost-cut recovery.
• Relative-value credit play: if MRK 5y spread widens >15bps to exceed ~40bps over Treasuries, buy MRK 5–7y investment‑grade bonds (target duration 4–6y) sized 1–2% portfolio to capture yield pickup versus equity downside.
• Catalyst-driven monitoring: within the next 90 days, reduce/add only after three triggers—(1) investor day confirms >$1.5bn net synergies from Cidara integration, (2) a favorable patent-litigation outcome on Januvia/Keytruda, or (3) analyst consensus EPS revisions move >10%—use these to scale positions by ±50%.